(Total Views: 609)
Posted On: 10/24/2021 8:25:11 AM
Post# of 8587
Plantar Fasciitis Market To Expand Profoundly; Approval For ActiPatch By FDA To Boost Market Revenue, Says Fortune Business Insights™
2021October20
Approval for ActiPatch by FDA to Boost Growth Prospects
The launch of ActiPatch as drug-free pain therapy for plantar fasciitis by BioElectronics Corporation is likely to facilitate the growth of the market. For instance, in February 2017, BioElectronics Corporation received FDA approval of ActiPatch as drug-free pain therapy for plantar fasciitis and osteoarthritis which was highly efficient in treatment and demonstrated no harmful effects in patients.
https://elmiradaily.com/2021/10/20/plantar-fa...-insights/
2021October20
Approval for ActiPatch by FDA to Boost Growth Prospects
The launch of ActiPatch as drug-free pain therapy for plantar fasciitis by BioElectronics Corporation is likely to facilitate the growth of the market. For instance, in February 2017, BioElectronics Corporation received FDA approval of ActiPatch as drug-free pain therapy for plantar fasciitis and osteoarthritis which was highly efficient in treatment and demonstrated no harmful effects in patients.
https://elmiradaily.com/2021/10/20/plantar-fa...-insights/
(6)
(0)
